Bandingkan Harga & Kinerja Jakarta Setiabudi Internasional Tbk (JSPT) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Jakarta Setiabudi Internasional Tbk dan Organon Pharma Indonesia Tbk.: Jakarta Setiabudi Internasional Tbk diperdagangkan di Rp1.500 (kapitalisasi pasar 3,22 T, volume 24 jam 73 rb), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Jakarta Setiabudi Internasional Tbk jauh lebih besar — sekitar 30,8× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| JSPT | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 3,22 T | 104,4 M |
Volume | 73 rb | — |
Lot | 730 | — |
Perputaran | 108 jt | — |
Harga Rata-rata | 1.479,5 | — |
Nilai Transaksi | 108 jt | — |
Harga Ekuilibrium Indikatif | 1.500 | — |
Volume Ekuilibrium Indikatif | 297 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Jakarta Setiabudi Internasional Tbk
PT. Jakarta Setiabudi Internasional Tbk (the Company) was established in the Republic of Indonesia within the framework of the Domestic Capital Investment Law No. 6 year 1968 as amended by Law No. 12 year 1970 based on Notarial Deed No. 4 dated July 2, 1975 of Imas Fatimah, S.H., as amended by Notarial Deed No. 15 dated September 11, 1975 of the same notary. At the first time until 1996 this company was focusing in construction. Leasing and office building maintanance and apartment surrounding Kuningan area, Jakarta.
Selengkapnya di halaman JSPT →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
